LON:OXB Oxford Biomedica (OXB) Share Price, News & Analysis GBX 458.50 +23.50 (+5.40%) As of 09/7/2026 12:25 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsInsider TradesNews and Trends About Oxford Biomedica Stock (LON:OXB) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Oxford Biomedica alerts:Sign Up Key Stats Today's Range 435▼ 461.5050-Day Range 424▼ 65452-Week Range 420▼ 952Volume1.75 million shsAverage Volume1.08 million shsMarket Capitalization£555.01 millionP/E RatioN/ADividend Yield4.57%Price TargetGBX 580.85Consensus RatingModerate Buy Company Overview Oxford Biomedica (LSE: OXB) is a quality and innovation-led cell and gene therapy CDMO with a mission to enable its clients to deliver life changing therapies to patients around the world. One of the original pioneers in cell and gene therapy, the Company has more than 25 years of experience in viral vectors; the driving force behind the majority of gene therapies. The Company collaborates with some of the world’s most innovative pharmaceutical and biotechnology companies, providing viral vector development and manufacturing expertise in lentivirus, adeno-associated virus (AAV) and adenoviral vectors. Oxford Biomedica’s world-class capabilities span from early-stage development to commercialisation. These capabilities are supported by robust quality-assurance systems, analytical methods and depth of regulatory expertise. Oxford Biomedica, a FTSE4Good constituent, is headquartered in Oxford, UK. It has locations across Oxfordshire, UK and near Boston, MA, US. Learn more at www.oxb.com and follow us on LinkedIn and YouTube. Read More Oxford Biomedica Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks37th Percentile Overall ScoreOXB MarketRank™: Oxford Biomedica scored higher than 37% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.8 / 5Analyst RatingModerate Buy Consensus RatingOxford Biomedica has received a consensus rating of Moderate Buy. The company's average rating score is 2.80, and is based on no strong buy ratings, 4 buy ratings, 1 hold rating, and no sell ratings.Upside PotentialOxford Biomedica has a consensus price target of GBX 580.85, representing about 26.7% upside from its current price of GBX 458.50.Amount of Analyst CoverageOxford Biomedica has only been the subject of 2 research reports in the past 90 days.Read more about Oxford Biomedica's stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of Oxford Biomedica is -17.03, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Oxford Biomedica is -17.03, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioOxford Biomedica has a P/B Ratio of 6.77. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Short InterestN/AShort Interest LevelN/A Short InterestThere is no current short interest data available for OXB. Dividend1.7 / 5Dividend StrengthWeak Dividend LeadershipOxford Biomedica is a leading dividend payer. It pays a dividend yield of 4.57%, putting its dividend yield in the top 25% of dividend-paying stocks.Dividend GrowthOxford Biomedica does not have a long track record of dividend growth.Read more about Oxford Biomedica's dividend. News and Social Media0.0 / 5News Sentiment0.00 News Coverage This WeekMarketBeat has tracked 4 news articles for Oxford Biomedica this week, compared to 0 articles on an average week. Company Ownership1.1 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Oxford Biomedica insiders have not sold or bought any company stock.Percentage Held by Insiders43.30% of the stock of Oxford Biomedica is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions32.41% of the stock of Oxford Biomedica is held by institutions.Read more about Oxford Biomedica's insider trading history. Receive OXB Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Oxford Biomedica and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. OXB Stock News HeadlinesDeutsche Bank Aktiengesellschaft Reiterates "Hold" Rating for Oxford Biomedica (LON:OXB)September 4, 2026 | americanbankingnews.comOxford Biomedica's (OXB) "Outperform" Rating Reiterated at Royal Bank Of CanadaSeptember 4, 2026 | americanbankingnews.comBlackRock and Vanguard already own THISInstitutions own roughly 88 percent of an overlooked American oil and natural gas company. BlackRock holds 32 million shares worth about 716 million dollars, while Vanguard owns 48 million shares worth nearly 1.1 billion dollars. The company generates approximately 3.2 billion dollars in operating income against a market value of only about 8 billion dollars, and it has signed a multi-year AI agreement with Palantir to improve equipment reliability and well performance. | Monument Traders Alliance (Ad)UK Stock Market News: Stelrad, Vaalco Energy, Oxford BiomedicaAugust 7, 2026 | ca.finance.yahoo.comJust above £6 today, here’s where this deeply undervalued FTSE biotech star ‘should’ be trading right nowJune 23, 2026 | uk.finance.yahoo.comOxford Biomedica outlines long-term growth ambitions at Capital Markets EventJune 20, 2026 | theglobeandmail.comHow Oxford Biomedica (LSE:OXB) Is Reframing Its Long Term Value Story Around £8.43May 22, 2026 | finance.yahoo.comHow I invested my first £1,000 in FTSE shares… and the mistakes I madeApril 25, 2026 | uk.finance.yahoo.comSee More Headlines OXB Stock Analysis - Frequently Asked Questions How have OXB shares performed this year? Oxford Biomedica's stock was trading at GBX 617 at the beginning of the year. Since then, OXB shares have decreased by 25.7% and is now trading at GBX 458.50. How were Oxford Biomedica's earnings last quarter? Oxford Biomedica plc (LON:OXB) issued its quarterly earnings data on Thursday, March, 26th. The biopharmaceutical company reported ($26.92) earnings per share (EPS) for the quarter. Oxford Biomedica had a negative trailing twelve-month return on equity of 48.56% and a negative net margin of 17.85%. Read the conference call transcript. How do I buy shares of Oxford Biomedica? Shares of OXB stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock. What other stocks do shareholders of Oxford Biomedica own? Based on aggregate information from My MarketBeat watchlists, some other companies that Oxford Biomedica investors own include EnQuest (ENQ), Petra Diamonds (PDL), Centamin (CEY), Lloyds Banking Group (LLOY), Oxford BioMedica (OXBDF) and Barclays (BARC). Company Calendar Last Earnings3/26/2026Today9/07/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeLON SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolLON:OXB CIKN/A Webwww.oxfordbiomedica.co.uk Phone+44-1865-783000FaxN/AEmployees891Year FoundedN/APrice Target and Rating Average Price Target for Oxford BiomedicaGBX 580.85 High Price TargetGBX 950 Low Price TargetGBX 8.27 Potential Upside/Downside+26.7%Consensus RatingModerate Buy Rating Score (0-4)2.80 Research Coverage5 Analysts Profitability EPS (Trailing Twelve Months)GBX (26.92) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-£143.51 million Net Margins-17.85% Pretax MarginN/A Return on Equity-48.56% Return on Assets-12.67% Debt Debt-to-Equity Ratio162.16 Current Ratio2.20 Quick Ratio1.67 Sales & Book Value Annual Sales£168.74 million Price / Sales3.29 Cash FlowGBX 152.50 per share Price / Cash Flow3.01 Book ValueGBX 67.70 per share Price / Book6.77Miscellaneous Outstanding Shares121,048,000Free FloatN/AMarket Cap£555.01 million OptionableNot Optionable Beta1.10 Don't Wait for the OpenAI IPOThe AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.Get This Free Report This page (LON:OXB) was last updated on 9/8/2026 by MarketBeat.com Staff. From Our PartnersA Simple Guide to Options Trading While It's Still FreeA free copy of Options Trading Made Simple is available now but wont stay that way for long. Chris Rowe cal...True Market Insiders | SponsoredWhy the Treasury still prices gold at 42 dollars an ounceThe U.S. Treasury still values its gold reserves at 42.22 dollars an ounce, a price set in 1973. Gold trades n...Golden Portfolio | SponsoredBlackRock and Vanguard already own THISInstitutions own roughly 88 percent of an overlooked American oil and natural gas company. BlackRock holds 32 ...Monument Traders Alliance | SponsoredHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | SponsoredEarth's biggest energy source: near Grand CanyonThe largest energy source on Earth contains 50,000 times every oil and gas reserve on the planet combined - an...Behind the Markets | SponsoredThe $15 Gold Fund That Pays Up to $1,152/MonthGold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying...Investors Alley | SponsoredElon Musk's next big bet has nothing to do with rocketsElon Musk's next major bet isn't rockets, it's a light speed technology making AI 100 times faster and more en...Brownstone Research | SponsoredBefore the Market Opens After Labor Day ...Uber fell 40% within six months of its IPO. Meta dropped nearly 50% in three months, and Robinhood plunged 85%...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Oxford Biomedica plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Oxford Biomedica With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
